NAIP-NLRC4-deficient mice are susceptible to shigellosis

  1. Patrick S Mitchell
  2. Justin L Roncaioli
  3. Elizabeth A Turcotte
  4. Lisa Goers
  5. Roberto A Chavez
  6. Angus Y Lee
  7. Cammie F Lesser
  8. Isabella Rauch
  9. Russell E Vance  Is a corresponding author
  1. University of California, Berkeley, United States
  2. Harvard Medical School, United States
  3. Massachusetts General Hospital, United States
  4. Oregon Health and Sciences University, United States

Abstract

Bacteria of the genus Shigella cause shigellosis, a severe gastrointestinal disease that is a major cause of diarrhea-associated mortality in humans. Mice are highly resistant to Shigella and the lack of a tractable physiological model of shigellosis has impeded our understanding of this important human disease. Here we propose that the differential susceptibility of mice and humans to Shigella is due to mouse-specific activation of the NAIP–NLRC4 inflammasome. We find that NAIP–NLRC4-deficient mice are highly susceptible to oral Shigella infection and recapitulate the clinical features of human shigellosis. Although inflammasomes are generally thought to promote Shigella pathogenesis, we instead demonstrate that intestinal epithelial cell (IEC)-specific NAIP–NLRC4 activity is sufficient to protect mice from shigellosis. In addition to describing a new mouse model of shigellosis, our results suggest that the lack of an inflammasome response in IECs may help explain the susceptibility of humans to shigellosis.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Patrick S Mitchell

    Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.
  2. Justin L Roncaioli

    Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.
  3. Elizabeth A Turcotte

    Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.
  4. Lisa Goers

    Department of Microbiology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  5. Roberto A Chavez

    Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.
  6. Angus Y Lee

    Department of Molecular & Cell Biology, University of California, Berkeley, Berkeley, United States
    Competing interests
    No competing interests declared.
  7. Cammie F Lesser

    Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Cambridge, United States
    Competing interests
    No competing interests declared.
  8. Isabella Rauch

    Department of Molecular Microbiology and Immunology, Oregon Health and Sciences University, Portland, United States
    Competing interests
    No competing interests declared.
  9. Russell E Vance

    Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
    For correspondence
    rvance@berkeley.edu
    Competing interests
    Russell E Vance, R.E.V. has a financial relationship with Aduro BioTech and Ventus Therapeutics and both he and the companies may benefit from the commercialization of the results of this research.Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6686-3912

Funding

Howard Hughes Medical Institute

  • Russell E Vance

National Institutes of Health (AI075039,AI063302)

  • Russell E Vance

National Institutes of Health (AI064285,AI128743)

  • Cammie F Lesser

Jane Coffin Childs Memorial Fund for Medical Research (Postdoctoral Fellowship)

  • Patrick S Mitchell

Irving H. Wiesenfeld CEND Fellow (Graduate Student Fellowship)

  • Justin L Roncaioli

UC Berkeley Department of Molecular and Cell Biology, NIH (Graduate Training Grant 5T32GM007232-42)

  • Elizabeth A Turcotte

Brit d'Arbeloff MGH Research Scholar

  • Cammie F Lesser

Medical Research Foundation (MRF2012)

  • Isabella Rauch

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (AUP-2014-09-6665-1) of the University of California Berkeley.

Copyright

© 2020, Mitchell et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,906
    views
  • 662
    downloads
  • 74
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Patrick S Mitchell
  2. Justin L Roncaioli
  3. Elizabeth A Turcotte
  4. Lisa Goers
  5. Roberto A Chavez
  6. Angus Y Lee
  7. Cammie F Lesser
  8. Isabella Rauch
  9. Russell E Vance
(2020)
NAIP-NLRC4-deficient mice are susceptible to shigellosis
eLife 9:e59022.
https://doi.org/10.7554/eLife.59022

Share this article

https://doi.org/10.7554/eLife.59022

Further reading

    1. Immunology and Inflammation
    Graham L Barlow, Christian M Schürch ... Paul L Bollyky
    Research Article

    In autoimmune type 1 diabetes (T1D), immune cells infiltrate and destroy the islets of Langerhans — islands of endocrine tissue dispersed throughout the pancreas. However, the contribution of cellular programs outside islets to insulitis is unclear. Here, using CO-Detection by indEXing (CODEX) tissue imaging and cadaveric pancreas samples, we simultaneously examine islet and extra-islet inflammation in human T1D. We identify four sub-states of inflamed islets characterized by the activation profiles of CD8+T cells enriched in islets relative to the surrounding tissue. We further find that the extra-islet space of lobules with extensive islet-infiltration differs from the extra-islet space of less infiltrated areas within the same tissue section. Finally, we identify lymphoid structures away from islets enriched in CD45RA+ T cells — a population also enriched in one of the inflamed islet sub-states. Together, these data help define the coordination between islets and the extra-islet pancreas in the pathogenesis of human T1D.

    1. Immunology and Inflammation
    Eugenio Antonio Carrera Silva, Juliana Puyssegur, Andrea Emilse Errasti
    Review Article

    The gut biome, a complex ecosystem of micro- and macro-organisms, plays a crucial role in human health. A disruption in this evolutive balance, particularly during early life, can lead to immune dysregulation and inflammatory disorders. ‘Biome repletion’ has emerged as a potential therapeutic approach, introducing live microbes or helminth-derived products to restore immune balance. While helminth therapy has shown some promise, significant challenges remain in optimizing clinical trials. Factors such as patient genetics, disease status, helminth species, and the optimal timing and dosage of their products or metabolites must be carefully considered to train the immune system effectively. We aim to discuss how helminths and their products induce trained immunity as prospective to treat inflammatory and autoimmune diseases. The molecular repertoire of helminth excretory/secretory products (ESPs), which includes proteins, peptides, lipids, and RNA-carrying extracellular vesicles (EVs), underscores their potential to modulate innate immune cells and hematopoietic stem cell precursors. Mimicking natural delivery mechanisms like synthetic exosomes could revolutionize EV-based therapies and optimizing production and delivery of ESP will be crucial for their translation into clinical applications. By deciphering and harnessing helminth-derived products’ diverse modes of action, we can unleash their full therapeutic potential and pave the way for innovative treatments.